Natapohn Chaipichit

Dr. Natapohn Chaipichit

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 December 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CNChalisa Nithuthorn
Chalisa Nithuthorn
NCNatapohn Chaipichit
Natapohn Chaipichit
TJThammasorn Jeeraaumponwat
Thammasorn Jeeraaumponwat
Mart MaiprasertMart Maiprasert
Mart Maiprasert
Piyameth DilokthornsakulPiyameth Dilokthornsakul
Piyameth Dilokthornsakul
Background: Pilates is one of the non-pharmacological interventions for fibromyalgia (FM). However, its impacts on pain and health-related quality of life (HRQOL) in fibromyalgia patients (FMPs) are inconclusive. This study aimed to assess the effects of Pilates on pain and HRQOL among FMPs. Methods: A systematic review and meta-analysis were conducted. Four databases—PubMed, ScienceDirect, Scopus, and Cochrane CENTRAL—along with one grey literature source, Google Scholar, were searched for randomized controlled trials comparing Pilates with other exercises or usual care in FMPs. The outcomes were pain and HRQOL. A meta-analysis was performed using a random-effects model. Results: Six studies were included (n = 265). We found that the effects of Pilates from each individual study on pain were inconsistent. Our pooled analysis of visual analog scale (VAS) scores demonstrated significant pain reduction (mean difference (MD), −0.71, 95%CI, −1.33 to −0.10, p = 0.023; (I2 = 29.3%, p = 0.226)). However, neither the algometric score (AS) nor tender point count (TPC) showed an insignificant difference (AS: MD, −0.43, 95%CI, −2.60 to 1.74, p = 0.700; (I2 = 0.0%, p = 0.654); TPC: MD, −0.16, 95%CI, −2.22 to 1.89, p = 0.520; (I2 = 0.0%, p = 0.515)). Regarding HRQOL, Pilates showed statistically significant improvements on the Fibromyalgia Impact Questionnaire (FIQ) (MD, −7.28, 95%CI, (−12.06 to −2.49), p = 0.003; (I2 = 95.7%, p < 0.001)). A sensitivity analysis of three RCTs (n = 176) based on the ACR 2010 supported this finding (MD, −7.68, 95% CI, −8.60 to −6.76, p < 0.001; (I2 = 0.0%, p = 0.832)) with non-important heterogeneity. Conclusions: Pilates may benefit FMPs. It could reduce pain and improve HRQOL. Given the small number of studies and the presence of data heterogeneity, future high-quality RCTs would provide a clearer conclusion.

23 January 2026 in Journal of Global Health
Verified
Journal Article
Open access
PSPattarapan Sukwuttichai
Pattarapan Sukwuttichai
NTNattapong Tidwong
Nattapong Tidwong
NCNatapohn Chaipichit
Natapohn Chaipichit
TDTeerapon Dhippayom
Teerapon Dhippayom
WDWitoo Dilokthornsakul
Witoo Dilokthornsakul
Piyameth DilokthornsakulPiyameth Dilokthornsakul
Piyameth Dilokthornsakul
Iron is a micronutrient that plays a critical role in oxygen transportation, energy production, and overall physiological growth at every stage of life. About 70% of the body’s total iron is localised in red blood cells (haemoglobin) and muscle cells (myoglobin), where it facilitates the efficient delivery and utilisation of oxygen [1]. During childhood, iron […]

9 September 2025 in International Journal of Pharmacy Practice
Verified
Journal Article
Closed access
SSSinwisuth Sutheechai
Sinwisuth Sutheechai
Buntitabhon SirichanchuenBuntitabhon Sirichanchuen
Buntitabhon Sirichanchuen
NCNatapohn Chaipichit
Natapohn Chaipichit
WDWitoo Dilokthornsakul
Witoo Dilokthornsakul
Objectives: Proton pump inhibitors (PPIs) are commonly used among these patients to prevent upper gastrointestinal bleeding (UGIB) in anticoagulated patients. However, their clinical benefits among patients receiving OACs with a history of UGIB remain inconclusive. This study aimed to summarize the clinical benefits of PPIs for the secondary prevention of recurrent UGIB among patients using OACs. Methods: A systematic search was performed in PubMed, EMBASE, Cochrane, and Scopus databases for clinical studies conducted among patients receiving OACs with PPIs and a history of UGIB. The primary outcome was the recurrent UGIB, analysed using a random-effect model. Heterogeneity was assessed by the I2-statistic. The quality of studies was assessed by the Newcastle-Ottawa Scale. Key findings and conclusions: Four studies with a total of 67 148 participants were included. Of those, three were conducted among patients with atrial fibrillation and one among unspecified patients. Our meta-analysis indicated that PPIs were associated with a lower risk of recurrent UGIB with a hazard ratio (HR) of 0.67 (95%CI; 0.58–0.76, I2 = 8.9%) compared with no PPIs for patients receiving oral anticoagulants. Our subgroup analysis using comparators showed the robustness of the main findings. The HR of PPIs for recurrent UGIB in patients receiving vitamin K antagonists and direct oral anticoagulants compared with no PPI were 0.67 (95%CI; 0.54–0.80, I2 = 0.0%) and 0.63 (95%CI; 0.52–0.74, I2 = 0.0%), respectively. PPIs could potentially reduce the risk of recurrent UGIB. Clinicians might consider using PPIs for secondary prevention among patients receiving OAC.

1 March 2026 in Patient Preference and Adherence
Verified
Journal Article
Open access
PDF file
SDSuteera Dawdan
Suteera Dawdan
NCNatapohn Chaipichit
Natapohn Chaipichit
ASApirak Sribhutorn
Apirak Sribhutorn
NJNarumol Jarernsiripornkul
Narumol Jarernsiripornkul
Purpose: To compare the outcomes of routine versus intensive adverse drug reaction (ADR) monitoring programs among adult in-patients initially treated with phenytoin, and to identify risk factors associated with severe cutaneous adverse reactions (SCARs). Patients and Methods: This retrospective cohort study recruited phenytoin-naïve patients treated at a general hospital in Northern Thailand. Potentially eligible admissions were identified through the electronic medical record by extracting all medication orders for phenytoin during October 2018 to May 2021. Patients were consecutively enrolled and divided into routine adverse drug reaction monitoring (n = 500, rADRM) and intensive adverse drug reaction monitoring (n = 500, iADRM) allocated based on ward-based monitoring models. All participants received standard counseling regarding phenytoin dosing and administration. The rADRM group underwent ADR monitoring during routine follow-up visits, while the iADRM group received additional individualized instruction on ADR recognition and access to a direct pharmacist contact for reporting suspected ADRs. Multivariable logistic regression was performed to identify independent risk factors for SCARs. Results: Patients in the intensive adverse drug reaction monitoring group had a significantly higher detection rate of phenytoin-induced ADRs compared with those in the routine adverse drug reaction monitoring group (OR 2.301, 95% CI 1.091:4.853, p = 0.029), as well as a greater patient-initiated reporting (OR 4.527, 95% CI 2.274:9.010, p < 0.001). Type B ADRs occurred in 3.6% of patients, with the iADRM group documenting more SCARs (36.84% vs. 5.88%, p = 0.044). Discontinuation of phenytoin and prolonged hospitalization were observed in both groups (42.1 vs. 52.9%, p = 0.045). Multivariable logistic regression identified iADRM (OR 13.304, 95% CI 1.183– 149.581, p = 0.036), comorbidities (OR 12.935, 95%Cl 1.514:110.48, p =0.019), omeprazole use (OR 57.112, 95%Cl 9.569:340.875, p < 0.001), and increased age (OR 0.940, 95%Cl 0.893:0.989, p =0.023) as significant risk factors associated with SCARs. Conclusion: Intensive ADR monitoring facilitates earlier detection and reporting of phenytoin-associated ADRs including SCARs. Comorbidities, concomitant omeprazole use, and older age were associated with SCARs. Intensive monitoring programs may enhance patient engagement and improve medication safety by enabling timely recognition and management of adverse reactions.